Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1118

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma NSCLC

Interventions

BIOLOGICAL: MEDI4736 (Durvalumab)
BIOLOGICAL: MEDI4736 (Durvalumab)+Tremelimumab
DRUG: Paclitaxel + Carboplatin
DRUG: Gemcitabine + Cisplatin
DRUG: Gemcitabine + Carboplatin
DRUG: Pemetrexed + Cisplatin
DRUG: Pemetrexed + Carboplatin
BIOLOGICAL: Tremelimumab

Sponsor

AstraZeneca